2CLisaB
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2CLisaB, also known as 2-[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]-1,2,3,4-tetrahydroisoquinoline, is a serotonin receptor modulator of the phenethylamine, 2C, and N-benzylphenethylamine families.[1][2][3][4] It is a cyclized phenethylamine analogue of the serotonergic psychedelic 25B-NBOMe in which the N-benzyl group has been cyclized with the amine to form a tetrahydroisoquinoline ring.[1][2] The drug shows affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 45–1,580 nM and 270–77,680 nM, respectively).[3][4] 2CLisaB was first described in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007.[1][2]
| |
| Clinical data | |
|---|---|
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C19H22BrNO2 |
| Molar mass | 376.294 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The compound without the 4-bromo substitution is known as 2CLisaH.[2] It shows much lower affinities for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 690–1,158 nM and 1,303–1,404 nM, respectively).[1][2]
